155 related articles for article (PubMed ID: 1722775)
1. Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin's lymphoma.
Fukuda H; Seya T; Hara T; Matsumoto M; Kinoshita T; Masaoka T
Immunol Lett; 1991 Aug; 29(3):205-9. PubMed ID: 1722775
[TBL] [Abstract][Full Text] [Related]
2. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies.
Hara T; Kojima A; Fukuda H; Masaoka T; Fukumori Y; Matsumoto M; Seya T
Br J Haematol; 1992 Oct; 82(2):368-73. PubMed ID: 1384649
[TBL] [Abstract][Full Text] [Related]
3. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
[TBL] [Abstract][Full Text] [Related]
4. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.
Guc D; Canpinar H; Kucukaksu C; Kansu E
Eur J Haematol; 2000 Jan; 64(1):3-9. PubMed ID: 10680700
[TBL] [Abstract][Full Text] [Related]
5. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
Matsumoto M; Sugita Y; Seya T
Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
[TBL] [Abstract][Full Text] [Related]
6. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
7. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
Kinoshita T; Medof ME; Silber R; Nussenzweig V
J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
[TBL] [Abstract][Full Text] [Related]
8. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
Ninomiya H; Kobayashi T; Abe T
Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
[TBL] [Abstract][Full Text] [Related]
9. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies.
Seya T; Matsumoto M; Hara T; Hatanaka M; Masaoka T; Akedo H
Leuk Lymphoma; 1994 Feb; 12(5-6):395-400. PubMed ID: 7514063
[TBL] [Abstract][Full Text] [Related]
10. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).
Seya T; Hara T; Matsumoto M; Sugita Y; Akedo H
J Exp Med; 1990 Dec; 172(6):1673-80. PubMed ID: 2258699
[TBL] [Abstract][Full Text] [Related]
11. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes.
Shichishima T; Terasawa T; Hashimoto C; Ohto H; Uchida T; Maruyama Y
Br J Haematol; 1991 Aug; 78(4):545-50. PubMed ID: 1716957
[TBL] [Abstract][Full Text] [Related]
12. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
Kuraya M; Yefenof E; Klein G; Klein E
Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
[TBL] [Abstract][Full Text] [Related]
13. Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma.
Sakuma T; Kodama K; Hara T; Eshita Y; Shibata N; Matsumoto M; Seya T; Mori Y
Jpn J Cancer Res; 1993 Jul; 84(7):753-9. PubMed ID: 7690355
[TBL] [Abstract][Full Text] [Related]
14. Localization of the complement regulatory proteins in the normal human kidney.
Ichida S; Yuzawa Y; Okada H; Yoshioka K; Matsuo S
Kidney Int; 1994 Jul; 46(1):89-96. PubMed ID: 7523758
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
Seya T; Kojima A; Hara T; Hazeki K; Sugita Y; Akedo H
Immunobiology; 1991 Sep; 183(1-2):115-24. PubMed ID: 1718846
[TBL] [Abstract][Full Text] [Related]
16. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
[TBL] [Abstract][Full Text] [Related]
17. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils.
Kawakami Z; Ninomiya H; Tomiyama J; Abe T
Br J Haematol; 1990 Apr; 74(4):508-13. PubMed ID: 1693286
[TBL] [Abstract][Full Text] [Related]
18. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
[TBL] [Abstract][Full Text] [Related]
19. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone.
Devine DV; Gluck WL; Rosse WF; Weinberg JB
J Clin Invest; 1987 Jan; 79(1):314-7. PubMed ID: 2432090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
